Pirtobrutinib showed noninferiority in ORR compared to ibrutinib in BTK inhibitor-naive CLL/SLL patients, with a favorable PFS trend. Safety profiles indicated fewer adverse events with pirtobrutinib, ...
Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.
Background Previous epidemiological studies demonstrated that premature atrial contractions (PACs) and premature ventricular ...
Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...
In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...
A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL ...
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with ...
HealthDay on MSN
American Society of Hematology, Dec. 6 to 9
The annual meeting of the American Society of Hematology was held from Dec. 6 to 9 in Orlando, Florida, and attracted ...
Pirtobrutinib significantly improved PFS in previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with a standard chemoimmunotherapy regimen in a ...
Jaypirca is approved for the treatment of adults with relapsed or refractory CLL/SLL who were previously treated with a ...
Background The PR interval is a ubiquitous parameter available to all clinicians. Studies on associated risk have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback